Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 3Melanoma 2Uveal Melanoma 1Skin Neoplasms 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms 1Neoplasm Metastasis 1Muscle Neoplasms 1Lung Neoplasms 1Histiocytoma, Malignant Fibrous 1Genetic Diseases, Inborn 1Gastrointestinal Neoplasms 1Eye Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Bone Neoplasms 1

Interventions

Paclitaxel 50Capecitabine 50Trastuzumab 38Fulvestrant 31pembrolizumab 27Cyclophosphamide 27Carboplatin 27Gemcitabine 23Letrozole 21palbociclib 19Docetaxel 19Lapatinib 18Bevacizumab 18exemestane 17eribulin 15Everolimus 14abemaciclib 13Vinorelbine 13Nivolumab 13Magnetic Resonance Spectroscopy 12Cisplatin 12Anastrozole 12trastuzumab deruxtecan 11Zoledronic Acid 11Doxorubicin 11Albumin-Bound Paclitaxel 11olaparib 10Tamoxifen 10Specimen Handling 10Radiotherapy 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × montanide ISA 51 × Breast × Clear all
NCT00001832 2012-12-21

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
170 enrolled 23 charts
BreastDermatologic

Breast Neoplasms, Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡